James Hayden, MD, PhD (he/him/his)

Associate Professor
Oregon Health & Science University

Poster(s):

• (P 130) THE ADOPTION OF MEDICAID EXPANSION IN THE AFFORDABLE CARE ACT IS NOT ASSOCIATED WITH STAGE AT PRESENTATION OR 5-YEAR OVERALL SURVIVAL FOR BONE OR SOFT TISSUE SARCOMAS

• (P 179) PILOT STUDY OF A REMOTELY DELIVERED RESISTANCE EXERCISE TRAINING PROGRAM IN SARCOMA SURVIVORS

• (P 462) EXTERNAL VALIDATION OF A NOMOGRAM PREDICTING THE RISK OF POSTOPERATIVE MAJOR WOUND COMPLICATION IN SOFT TISSUE SARCOMA FOLLOWING PREOPERATIVE RADIOTHERAPY AND RESECTION

• (P 463) MACHINE LEARNING CORROBORATES TRADITIONAL REGRESSION TECHNIQUES IN PREDICTING MAJOR WOUND COMPLICATIONS AFTER SOFT TISSUE SARCOMA RESECTION WITHOUT IMPROVEMENTS IN PREDICTIVE PERFORMANCE